HYRIMOZ® is an adalimumab biosimilar manufactured by Sandoz Inc. and indicated for the treatment of various inflammatory conditions.

21 мар. 2023 г. · Sandoz intends to launch the Hyrimoz citrate-free HCF in the US on July 1, 2023. “As one of the first adalimumab high-concentration formulation ...

23 авг. 2023 г. · Sandoz AG and Cordavis announce agreement to commercialize Hyrimoz® (adalimumab-adaz) in US under Cordavis private label ...

21 нояб. 2023 г. · Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care | Sandoz.

31 окт. 2018 г. · Hyrimoz is a trademark of Novartis AG. Please see full Prescribing Information for HyrimozTM here .

15 мая 2024 г. · Brand name: Hyrimoz Generic name: adalimumab-adaz. Dosage form: Injection Company: Sandoz Inc. Treatment for: Rheumatoid Arthritis, Juvenile ...

21 нояб. 2023 г. · Basel, November 21, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Hyrimoz® (adalimumab).

23 авг. 2023 г. · As its first product, Cordavis has contracted with Sandoz to commercialize and bring to market Hyrimoz® (adalimumab-adaz), a biosimilar for ...

In 2024 Cordavis will work with Novartis' biosimilar division, Sandoz. Together they will market Hyrimoz, a version of Humira (adalimumab), AbbVie's ...